Quick Answer
Lakefront Biotherapeutics NV reported R&D Expense of $459.42 million for fiscal year 2025.
Lakefront Biotherapeutics NV R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $459.42M | +37.0% |
| 2024 | $335.46M | +39.0% |
| 2023 | $241.29M | -10.6% |
| 2022 | $269.80M | -15.8% |
| 2021 | $320.50M | -38.8% |
| 2020 | $523.67M | +24.7% |
| 2019 | $420.09M | +32.8% |
| 2018 | $316.22M | +44.7% |
| 2017 | $218.50M | +56.6% |
| 2016 | $139.57M | +7.6% |
| 2015 | $129.71M | — |
- Lakefront Biotherapeutics NV showed an increase of +37.0% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Lakefront Biotherapeutics NV’s r&d expense has grown by 254.2% (from $129.71 million to $459.42 million).
- The most recent figure is from Lakefront Biotherapeutics NV’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: